Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans
about
How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.Indolealkylamines: biotransformations and potential drug-drug interactionsComputational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.Oral almotriptan: practical uses in the acute treatment of migraine.Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?Almotriptan in the treatment of migraine.Almotriptan: a review of 10 years' clinical experience.Drug interactions with triptans : which are clinically significant?High performance liquid chromatographic analysis of almotriptan malate in bulk and tablets.Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study.Development and Validation of HPTLC Method for the Estimation of Almotriptan Malate in Tablet Dosage Form.Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.Interaction between ketoconazole and almotriptan in healthy volunteers.A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults.Oral sumatriptan and almotriptan--delimiting the MAOI effect.Pharmacokinetic evaluation of almotriptan for the treatment of migraines.
P2860
Q30692301-6DBF01EF-5B75-4489-B420-5EAF4954200FQ34775667-33B7E9BF-6347-4619-AF34-7625CA119417Q35646205-20D257AE-3E69-45C6-860C-44A0E26C5DBEQ35825843-6BA474EF-ACAD-43B8-BEA9-52BFF132CC9EQ36106933-5A82AA73-A9B5-4BDB-99A9-A7CCF7751A03Q36941961-738E78D1-5DB2-4060-96B8-9416E11C4666Q37129812-D58D1698-B13F-4F57-8335-1B02F83A79FBQ37800072-92C808E8-9509-4221-B216-FC66DF2ABA1BQ38047218-40DE42C5-DEAD-4B58-8B04-D3E3DB1FF59BQ42012921-57E0C16D-6111-4B4B-9C31-84EE8CD4ECDDQ42122554-F0A45303-85B0-4C7B-BFD7-1F2DF678BEACQ42731793-3086689E-0925-450E-879C-FA76749E4C0EQ44237114-C209DF9D-37B9-4BAB-8346-526F22A624F9Q44424388-C995C48C-B7AC-4F4C-B6B4-50441BB87C77Q44805088-29AD5192-F0A7-46A2-B53E-06206BC30F3FQ46045347-ADDAD98A-EC2F-4892-9BC2-25082A0091B0Q50490563-4F41F8DD-617C-4C32-AAAF-84C6F6E07B05
P2860
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@ast
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@en
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@nl
type
label
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@ast
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@en
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@nl
prefLabel
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@ast
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@en
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@nl
P2093
P2860
P1476
Effect of MAO-A inhibition on ...... n antimigraine agent in humans
@en
P2093
J C Fleishaker
J M Jansat
P2860
P304
P356
10.1046/J.1365-2125.2001.01367.X
P407
P577
2001-05-01T00:00:00Z